XTL Biopharmaceuticals Ltd.(XTLB)Earnings, Financials & Key Ratios
XTLB•NASDAQ
Price updated Jun 19, 2026
AboutXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.Show more
- Revenue$451K
- EBITDA-$2M-158.2%
- Net Income-$1M-57531.9%
- EPS (Diluted)-9.60
- Gross Margin0.67%
- EBITDA Margin-437.47%
- Operating Margin-481.6%
- Net Margin-227.72%
- ROE-26.83%-46727.4%
XTLB Key Insights
XTL Biopharmaceuticals Ltd. (XTLB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 29.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XTLB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XTLB Price & Volume
XTL Biopharmaceuticals Ltd. (XTLB) stock price & volume — 10-year historical chart
Loading chart...
XTLB Growth Metrics
XTL Biopharmaceuticals Ltd. (XTLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.37%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.45%
Return on Capital
10 Years-31.57%
5 Years-24.59%
3 Years-30.76%
Last Year-50.73%
XTLB Peer Comparison
XTL Biopharmaceuticals Ltd. (XTLB) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 BFRI | 12.64M | 0.99 | -1.10 | 11.8% | -25.66% | -476.72% | 0.59 | |
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 |
Compare XTLB vs Peers
XTL Biopharmaceuticals Ltd. (XTLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XTLB Income Statement
XTL Biopharmaceuticals Ltd. (XTLB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 451K |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 1K | 1K | 1K | 0 | 448K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 99.33% |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1K▲ 0% | -1K▲ 0.0% | -1K▲ 0.0% | 0▲ 100.0% | 3K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | 0.67% |
Gross Profit Growth % | - | - | - | - | - | 0% | 0% | 100% | - |
Operating Expenses | 1.71M | 1.25M | 793K | 842K | 948K | 1.03M | 880K | 765K | 2.17M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | 482.26% |
Selling, General & Admin | 1.26M | 1.19M | 755K | 807K | 910K | 1M | 850K | 734K | 2.05M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | 453.66% |
Research & Development | 443K | 43K | 38K | 35K | 38K | 30K | 30K | 31K | 98K |
R&D % of Revenue | - | - | - | - | - | - | - | - | 21.73% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31K |
Operating Income | -2.56M▲ 0% | -1.25M▲ 51.3% | -793K▲ 36.4% | -842K▼ 6.2% | -948K▼ 12.6% | -1.03M▼ 8.8% | -880K▲ 14.6% | -765K▲ 13.1% | -2.17M▼ 183.9% |
Operating Margin % | - | - | - | - | - | - | - | - | -481.6% |
Operating Income Growth % | 29.08% | 51.35% | 36.36% | -6.18% | -12.59% | -8.76% | 14.65% | 13.07% | -183.92% |
EBITDA | -2.56M | -1.25M | -792K | 0 | -947K | -1.03M | -879K | -764K | -1.97M |
EBITDA Margin % | - | - | - | - | - | - | - | - | -437.47% |
EBITDA Growth % | 29.02% | 51.33% | 36.39% | 100% | - | -8.76% | 14.66% | 13.08% | -158.25% |
D&A (Non-Cash Add-back) | 3K | 1K | 1K | 842K | 1K | 1K | 1K | 1K | 199K |
EBIT | -1.71M | -1.25M | -793K | -842K | -948K | -1.03M | -880K | -765K | -1.13M |
Net Interest Income | 0 | 8K | 80K | 64K | 16K | -13K | 25K | 37K | -52K |
Interest Income | 0 | 16K | 87K | 93K | 33K | 8K | 36K | 41K | 34K |
Interest Expense | 0 | 8K | 7K | 29K | 17K | 21K | 11K | 4K | 86K |
Other Income/Expense | 16K | 465K | 4.42M | 79K | -2.01M | 1.47M | -468K | -1.02M | 1.01M |
Pretax Income | -2.54M▲ 0% | -781K▲ 69.3% | 2.99M▲ 482.3% | -1.35M▼ 145.1% | -2.95M▼ 119.3% | 435K▲ 114.7% | -1.35M▼ 409.9% | -1.78M▼ 32.2% | -1.16M▲ 35.1% |
Pretax Margin % | - | - | - | - | - | - | - | - | -256.54% |
Income Tax | 0 | 0 | -80K | -69K | 0 | 0 | 0 | 0 | -130K |
Effective Tax Rate % | 0% | 0% | -2.68% | 5.12% | 0% | 0% | 0% | 0% | 11.24% |
Net Income | -2.54M▲ 0% | -781K▲ 69.3% | 2.99M▲ 482.3% | -1.35M▼ 145.1% | -782K▲ 41.9% | 435K▲ 155.6% | -1.35M▼ 409.9% | -1.78K▲ 99.9% | -1.03M▼ 57531.9% |
Net Margin % | - | - | - | - | - | - | - | - | -227.72% |
Net Income Growth % | 40.97% | 69.31% | 482.33% | -145.11% | 41.95% | 155.63% | -409.89% | 99.87% | -57531.87% |
Net Income (Continuing) | -2.54M | -781K | 3.63M | -763K | -2.95M | 435K | -1.35M | -1.78M | -1.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -59.52▲ 0% | -10.88▲ 81.7% | 37.12▲ 441.2% | -16.64▼ 144.8% | -36.48▼ 119.2% | 4.48▲ 112.3% | -16.00▼ 457.1% | 0.00▲ 100.0% | -9.60▲ 0% |
EPS Growth % | 42.94% | 81.72% | 441.18% | -144.83% | -119.23% | 112.28% | -457.14% | 100% | - |
EPS (Basic) | -59.52 | -10.88 | 37.12 | -16.64 | -36.48 | 5.12 | -16.00 | 0.00 | -9.60 |
Diluted Shares Outstanding | 42.82K | 73.47K | 80.34K | 80.34K | 80.34K | 96.18K | 85.14K | 85.14K | 110.03K |
Basic Shares Outstanding | 42.82K | 73.47K | 80.34K | 80.34K | 80.34K | 83.12K | 85.17K | 85.15K | 105.16K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
XTLB Balance Sheet
XTL Biopharmaceuticals Ltd. (XTLB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.75M | 6.21M | 8.2M | 6.83M | 6.12M | 6.24M | 3.81M | 2.05M | 1.34M |
Cash & Short-Term Investments | 2.43M | 6.09M | 8.12M | 6.73M | 6.04M | 6.13M | 3.72M | 2.01M | 1.14M |
Cash Only | 2.02M | 3.29M | 3.25M | 4.46M | 3.63M | 2.97M | 2.09M | 1.4M | 371K |
Short-Term Investments | 414K | 2.81M | 4.87M | 2.27M | 2.41M | 3.16M | 1.63M | 605K | 772K |
Accounts Receivable | 12K | 0 | 0 | 0 | 0 | 94K | 71K | 29K | 99K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | 80.12 |
Inventory | 130K | 85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 179K | 0 | 0 | 20K | 13K | -78K | -57K | -18K | 47K |
Total Non-Current Assets | 263K | 380K | 380K | 382K | 382K | 381K | 380K | 380K | 7.21M |
Property, Plant & Equipment | 10K | 0 | 0 | 2K | 2K | 1K | 0 | 0 | 187K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 2.41x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.19M |
Intangible Assets | 253K | 380K | 380K | 380K | 380K | 380K | 380K | 380K | 3.82M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14K |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 3.02M▲ 0% | 6.59M▲ 118.3% | 8.57M▲ 30.2% | 7.21M▼ 15.9% | 6.5M▼ 9.8% | 6.62M▲ 1.8% | 4.19M▼ 36.7% | 2.43M▼ 42.0% | 8.55M▲ 252.4% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.05x |
Asset Growth % | -43.32% | 118.3% | 30.2% | -15.9% | -9.83% | 1.77% | -36.75% | -42.04% | 252.43% |
Total Current Liabilities | 330K | 300K | 253K | 232K | 254K | 231K | 187K | 206K | 2.21M |
Accounts Payable | 17K | 4K | 253K | 1K | 2K | 2K | 2K | 1K | 196K |
Days Payables Outstanding | - | - | - | - | 730 | 730 | 730 | - | 159.69 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 138K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18K |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.33M |
Current Ratio | 8.35x | 20.69x | 32.39x | 29.44x | 24.10x | 27.00x | 20.35x | 9.93x | 0.61x |
Quick Ratio | 7.95x | 20.40x | 32.39x | 29.44x | 24.10x | 27.00x | 20.35x | 9.93x | 0.61x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 2.67M | 0 | 465K | 2.64M | 1.05M | 0 | 0 | 908K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 219K |
Other Non-Current Liabilities | 0 | 2.67M | 0 | 465K | 2.64M | 1.05M | 0 | 0 | 689K |
Total Liabilities | 330K | 2.97M | 253K | 232K | 254K | 1.28M | 187K | 206K | 3.12M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 138K |
Net Debt | -2.02M | -3.29M | -3.25M | -4.46M | -3.63M | -2.97M | -2.09M | -1.4M | -233K |
Debt / Equity | - | - | - | - | - | - | - | - | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | - | -155.75x | -113.29x | -29.03x | -55.77x | -49.10x | -80.01x | -191.30x | -13.13x |
Total Equity | 2.69M▲ 0% | 3.62M▲ 34.7% | 8.32M▲ 130.0% | 6.98M▼ 16.1% | 6.25M▼ 10.5% | 5.33M▼ 14.7% | 4M▼ 25.0% | 2.22M▼ 44.5% | 5.43M▲ 144.8% |
Equity Growth % | -45.02% | 34.69% | 129.95% | -16.13% | -10.47% | -14.66% | -25.01% | -44.49% | 144.82% |
Book Value per Share | 62.75 | 49.26 | 103.58 | 86.88 | 77.78 | 55.45 | 46.97 | 26.07 | 49.40 |
Total Shareholders' Equity | 2.69M | 3.62M | 8.32M | 6.98M | 3.61M | 5.33M | 4M | 2.22M | 5.43M |
Common Stock | 6.62M | 13.18M | 13.18M | 13.18M | 13.18M | 14.12M | 14.12M | 14.12M | 23.14M |
Retained Earnings | -154.9M | -155.65M | -152.59M | -153.93M | -155.6M | -155.13M | -156.47M | -158.25M | -159.01M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 183K | 67K | 20K | 20K | 20K | 20K | 20K | 20K | 20K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XTLB Cash Flow Statement
XTL Biopharmaceuticals Ltd. (XTLB) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.73M | -1.13M | -816K | -908K | -850K | -1.05M | -901K | -707K | -1.62M |
Operating CF Margin % | - | - | - | - | - | - | - | - | -358.76% |
Operating CF Growth % | 6.93% | 35.05% | 27.47% | -11.27% | 6.39% | -23.41% | 14.11% | 21.53% | -128.85% |
Net Income | -2.54M | -781K | 2.99M | -1.35M | -2.95M | 435K | -1.35M | -1.78M | -1.03M |
Depreciation & Amortization | 3K | 1K | 0 | 0 | 1K | 1K | 1K | 0 | 199K |
Stock-Based Compensation | 182K | 40K | 24K | 5K | 51K | 37K | 14K | 3K | 264K |
Deferred Taxes | -182K | -755K | 0 | 0 | 0 | 0 | 487K | 0 | -130K |
Other Non-Cash Items | 848K | -437K | -3.82M | 484K | 2.01M | -1.47M | -36K | 1.01M | -1.11M |
Working Capital Changes | -220K | 52K | -8K | -50K | 45K | -54K | -19K | 64K | 189K |
Change in Receivables | -114 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -101K | -13K | -47K | -21K | 22K | -23K | -44K | 19K | 208K |
Cash from Investing | -66K | -2.5M | 778K | 2.11M | 32K | 8K | 36K | 41K | -844K |
Capital Expenditures | -66K | 0 | 0 | -2K | -1K | 0 | 0 | 0 | -54K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | 11.97% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -410K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -64K | 5K | 74K | 93K | 33K | 8K | 36K | 41K | -366K |
Cash from Financing | 0 | 4.89M | 0 | 0 | 0 | 385K | 0 | 0 | 1.45M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13K |
Equity Issued (Net) | 0 | 4.89M | 0 | 0 | 0 | 385K | 0 | 0 | 1.46M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | -1.8M▲ 0% | 1.27M▲ 170.6% | -34K▼ 102.7% | 1.2M▲ 3629.4% | -824K▼ 168.7% | -662K▲ 19.7% | -875K▼ 32.2% | -693K▲ 20.8% | -1.03M▼ 48.6% |
Free Cash Flow | -1.8M▲ 0% | -1.13M▲ 37.4% | -816K▲ 27.5% | -910K▼ 11.5% | -851K▲ 6.5% | -1.05M▼ 23.3% | -901K▲ 14.1% | -707K▲ 21.5% | -1.67M▼ 136.5% |
FCF Margin % | - | - | - | - | - | - | - | - | -370.73% |
FCF Growth % | 6.69% | 37.43% | 27.47% | -11.52% | 6.48% | -23.27% | 14.11% | 21.53% | -136.49% |
FCF per Share | -41.99 | -15.31 | -10.16 | -11.33 | -10.59 | -10.91 | -10.58 | -8.30 | -15.20 |
FCF Conversion (FCF/Net Income) | 0.68x | 1.44x | -0.27x | 0.67x | 1.09x | -2.41x | 0.67x | 396.75x | 1.58x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XTLB Key Ratios
XTL Biopharmaceuticals Ltd. (XTLB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -90.13% | -67.2% | -24.77% | 50.01% | -17.61% | -11.82% | 7.51% | -28.89% | -0.06% | -26.83% |
Return on Invested Capital (ROIC) | -150.88% | -221.03% | -187.27% | -22.04% | -16.64% | -27.65% | -31.04% | -30.92% | -42.13% | -54.11% |
Gross Margin | - | - | - | - | - | - | - | - | - | 0.67% |
Net Margin | - | - | - | - | - | - | - | - | - | -227.72% |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.03x |
Interest Coverage | - | - | -155.75x | -113.29x | -29.03x | -55.77x | -49.10x | -80.01x | -191.30x | -13.13x |
FCF Conversion | 0.43x | 0.68x | 1.44x | -0.27x | 0.67x | 1.09x | -2.41x | 0.67x | 396.75x | 1.58x |
Related:XTLB Dividend History·XTLB Revenue History·XTLB Price History·XTLB P/E History·XTLB Financial Ratios·XTLB Institutional Holders
XTLB Frequently Asked Questions
XTL Biopharmaceuticals Ltd. (XTLB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
XTL Biopharmaceuticals Ltd. (XTLB) reported $0.5M in revenue for fiscal year 2024.
XTL Biopharmaceuticals Ltd. (XTLB) grew revenue by 0.0% over the past year. Growth has been modest.
XTL Biopharmaceuticals Ltd. (XTLB) reported a net loss of $1.0M for fiscal year 2024.
Dividend & Returns
XTL Biopharmaceuticals Ltd. (XTLB) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.
XTL Biopharmaceuticals Ltd. (XTLB) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.